Assessment of the Global and Regional Impact of Kidney Cancer from 1990 to 2021: Insights and Future Projections from the Global Burden of Disease Study - Top-Institutions - MDSpire

Assessment of the Global and Regional Impact of Kidney Cancer from 1990 to 2021: Insights and Future Projections from the Global Burden of Disease Study

  • By

  • Deng Li

  • Haochen Zhao

  • Siqi Fan

  • Jingxing Bai

  • Linfen Guo

  • Jia You

  • Wei Li

  • Xuewen Xu

  • October 28, 2025

  • 0 min

Share

Top Institutions in Urology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Oncology
    • Urology
    • Genitourinary Cancer Research

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology
    • Genitourinary Oncology
    • Cancer Epidemiology

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Oncology
    • Urology
    • Cancer Therapeutics

  • #4

    National Cancer Institute (NCI)
    National Cancer Institute (NCI)

    Bethesda, MD

    Key Differentiators

    • Cancer Epidemiology
    • Oncology Research
    • Clinical Trials

  • #5

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Oncology
    • Urology
    • Translational Cancer Research

Original Source(s)

Assessment of the Global and Regional Impact of Kidney Cancer from 1990 to 2021: Insights and Future Projections from the Global Burden of Disease Study

  • by Deng Li, Haochen Zhao, Siqi Fan, Jingxing Bai, Linfen Guo, Jia You, Wei Li, Xuewen Xu

  • October 28, 2025

Related Content

Case review: adult epithelial type Wilms tumor in a 23-year-old female

Percutaneous nephrostomy as a marker of clinical vulnerability in non-metastatic muscle-invasive bladder cancer: prognostic and infectious implications

Roswell Park Experts Report on Discovery of Rare Bladder Cells, Neural Mapping of Pelvic Floor Muscles at AUA 2026

Evidence provided by a Roswell Park study indicates that neoadjuvant chemotherapy may be the preferred course of treatment for patients with non-muscle-invasive bladder cancer (NMIBC) when their disease progresses and they are diagnosed with muscle-invasive bladder cancer (MIBC)

  • by

  • May 19, 2026

  • 7 min